Dannielle Appelhans
Directeur/Membre du Conseil chez GENERATION BIO CO.
Fortune : 63 600 $ au 31/05/2024
Postes actifs de Dannielle Appelhans
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GENERATION BIO CO. | Directeur/Membre du Conseil | 15/07/2022 | - |
Cour Pharmaceuticals Development Co., Inc.
 Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Directeur des opérations | 19/07/2023 | - |
Historique de carrière de Dannielle Appelhans
Anciens postes connus de Dannielle Appelhans
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| RUBIUS THERAPEUTICS | Directeur Général | 15/11/2022 | 03/03/2023 |
| Directeur des opérations | 09/08/2021 | 15/11/2022 | |
| President | 15/11/2022 | 03/03/2023 | |
| AVEXIS INC | Directeur Technique/Scientifique/R&D | 01/01/2020 | 01/01/2021 |
Formation de Dannielle Appelhans
| MIT Sloan School of Management | Masters Business Admin |
| University of Michigan | Undergraduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Chief Operating Officer | 2 |
| Chief Executive Officer | 1 |
| President | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GENERATION BIO CO. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Cour Pharmaceuticals Development Co., Inc.
Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Health Technology |
- Bourse
- Insiders
- Dannielle Appelhans
- Expérience
